{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:52:55Z","timestamp":1784872375713,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Follicular lymphoma (FL) is a prevalent indolent non\u2010Hodgkin lymphoma (NHL) characterized by a relapsing course and eventual refractoriness to therapy. Despite advancements in treatment, FL remains incurable, necessitating ongoing research into novel therapeutic strategies. This review provides a comprehensive overview of current standard treatments for relapsed or refractory (R\/R) FL, including chemoimmunotherapy and stem cell transplantation, and delves into emerging therapies such as chimeric antigen receptor (CAR) T\u2010cell therapy and bispecific antibodies. We discuss the efficacy and safety profiles of these innovative treatments, their integration into existing treatment paradigms, and the potential they hold in altering the natural history of FL. Additionally, we explore the challenges associated with these therapies, including accessibility, cost, and long\u2010term management of adverse effects. By examining the evolving therapeutic landscape, this review aims to provide insights into future directions for achieving sustained remission and improving the quality of life in patients with R\/R FL.<\/jats:p>","DOI":"10.1111\/ejh.14401","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:44:51Z","timestamp":1740001491000},"page":"775-784","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Relapsed\/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives"],"prefix":"10.1111","volume":"114","author":[{"given":"Giulio","family":"Carid\u00e0","sequence":"first","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"},{"name":"Department of Experimental and Clinical Medicine University of Catanzaro  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Antonia","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-2404","authenticated-orcid":false,"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Caracciolo","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine University of Catanzaro  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Labanca","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Olivito","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Rossi","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Research Azienda USL\u2010IRCSS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"Scientific Directorate, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine University of Catanzaro  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine University of Catanzaro  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-7073","authenticated-orcid":false,"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Gruppo Amici Dell'Ematologia Foundation\u2010GrADE  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology  Cosenza Italy"},{"name":"Department of Pharmacy, Health and Nutritional Science University of Calabria  Rende Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0132-x"},{"key":"e_1_2_13_3_1","unstructured":"D.Singh A.Singh andS. K. R.Mukkamalla \u201cRelapsed and Refractory Follicular Lymphoma \u201d(2023) StatPearls."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3151-2"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2021.09.29"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2022.2022037"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284538"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0057"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_13_14_1","first-page":"2267","article-title":"Follicular Lymphoma Grade 3B: Low Grade, High Grade or Should We Skip the Grade?","volume":"108","author":"Mulvey E.","year":"2023","journal-title":"Haematologica"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2023.018"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04025-2"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70049"},{"issue":"12","key":"e_1_2_13_18_1","article-title":"Early Progression Beyond First\u2010Line Chemoimmunotherapy in Follicular Lymphoma: Insights From a Fondazione Italiana Linfoma (FIL) Study","volume":"8","author":"Bavieri A.","year":"2024","journal-title":"Hema"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5853"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30089-4"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010298"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.797440"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.04.001"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"issue":"28","key":"e_1_2_13_29_1","first-page":"325","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Follicular Lymphoma: The Phase 2 ELARA Trial","volume":"282","author":"Fowler N. H.","year":"2021","journal-title":"Nature Medicine"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14335"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01216-w"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147652"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624320"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00937-8"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_2_13_42_1","first-page":"2177","article-title":"Matching\u2010Adjusted Indirect Comparison From the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) Study to a Clinical Trial of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma","volume":"109","author":"Maurer M. J.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184653"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7509"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:08:09Z","timestamp":1754914089000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/ejh.14401"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14401","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"2025-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}